Search research articles
Contact Us
Filters
Showing results (101-110 of 112) with videos related to
Page
of 12
Sort By:
Journal for Immunotherapy of Cancer
|
June 27, 2017
New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31<sup>st</sup>Annual Meeting of the Society for Immunotherapy of Cancer, 2016
Prasad S Adusumilli, Edward Cha, Mark Cornfeld, et al.
Blood
|
May 27, 2021
CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel
Vicki Plaks, John M Rossi, Justin Chou, et al.
Nature Medicine
|
August 29, 2022
Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma
Nathalie Scholler, Regis Perbost, Frederick L Locke, et al.
Nature Medicine
|
January 17, 2024
Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma
Frederick L Locke, Simone Filosto, Justin Chou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 15, 2017
Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels
James N Kochenderfer, Robert P T Somerville, Tangying Lu, et al.
Blood Advances
|
July 20, 2022
Discovery of a novel genomic alteration that renders leukemic cells resistant to CD19-targeted immunotherapies
Armin Ghobadi, Jack H Landmann, Alun Carter, et al.
Nature Medicine
|
February 9, 2021
TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers
Nisha B Nagarsheth, Scott M Norberg, Andrew L Sinkoe, et al.
Blood
|
April 7, 2021
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results
Bijal D Shah, Michael R Bishop, Olalekan O Oluwole, et al.
The Lancet. Oncology
|
December 7, 2018
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L Locke, Armin Ghobadi, Caron A Jacobson, et al.
The New England Journal of Medicine
|
December 12, 2017
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Sattva S Neelapu, Frederick L Locke, Nancy L Bartlett, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 112) with videos related to
Sort By:
Page
of 12
Journal for Immunotherapy of Cancer
|
June 27, 2017
New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31<sup>st</sup>Annual Meeting of the Society for Immunotherapy of Cancer, 2016
Prasad S Adusumilli, Edward Cha, Mark Cornfeld, et al.
Blood
|
May 27, 2021
CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel
Vicki Plaks, John M Rossi, Justin Chou, et al.
Nature Medicine
|
August 29, 2022
Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma
Nathalie Scholler, Regis Perbost, Frederick L Locke, et al.
Nature Medicine
|
January 17, 2024
Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma
Frederick L Locke, Simone Filosto, Justin Chou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 15, 2017
Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels
James N Kochenderfer, Robert P T Somerville, Tangying Lu, et al.
Blood Advances
|
July 20, 2022
Discovery of a novel genomic alteration that renders leukemic cells resistant to CD19-targeted immunotherapies
Armin Ghobadi, Jack H Landmann, Alun Carter, et al.
Nature Medicine
|
February 9, 2021
TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers
Nisha B Nagarsheth, Scott M Norberg, Andrew L Sinkoe, et al.
Blood
|
April 7, 2021
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results
Bijal D Shah, Michael R Bishop, Olalekan O Oluwole, et al.
The Lancet. Oncology
|
December 7, 2018
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L Locke, Armin Ghobadi, Caron A Jacobson, et al.
The New England Journal of Medicine
|
December 12, 2017
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Sattva S Neelapu, Frederick L Locke, Nancy L Bartlett, et al.
Page
of 12